NCT01250366View on ClinicalTrials.gov

Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

March 31, 2011

Study Completion Date

June 30, 2011

Conditions
HCV (Genotype 1)
Interventions
DRUG

INX-08189

Capsules, Oral, 9 mg, Once Daily, 7 Days

DRUG

INX-08189

Capsule, Oral, 25 mg, Once Daily, 7 days

DRUG

INX-08189

Capsules, Oral, 50 mg, Single Dose, 1 day

DRUG

INX-08189

Capsules, Oral, 9 mg, Once daily, 6 days

DRUG

INX-08189

Capsules, Oral, 50 mg, Once daily, 7 days

DRUG

INX-08189

Capsules, Oral, 9 mg, Once daily, 7 days

DRUG

INX-08189

Capsules, Oral, 100 mg, Once daily, 7 days

DRUG

Placebo matching with INX-08189

Capsules, Oral, 0 mg, Once daily, 7 days

DRUG

Ribavirin

Capsules, Oral, 1000 or 1200 mg daily (delivered in weight-adjusted am/pm divided dose), 7 days

Trial Locations (4)

Unknown

Los Angeles

Plymouth

San Antonio

San Juan

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY